Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases

Daniel Fadaei Fouladi, Manijeh Zarghampour, Pallavi Pandey, Ankur Pandey, Farnaz Najmi Varzaneh, Mounes Aliyari Ghasabeh, Pegah Khoshpouri, Ihab R Kamel

Research output: Contribution to journalArticle

Abstract

Objectives: To examine the value of baseline 3D-ADC and to predict short-term response to treatment in patients with hepatic colorectal metastases (CLMs). Methods: Liver MR images of 546 patients with CLMs (2008–2015) were reviewed retrospectively and 68 patients fulfilled inclusion criteria. Patients had received systemic chemotherapy (n = 17), hepatic trans-arterial chemoembolization or TACE (n = 34), and 90Y radioembolization (n = 17). Baseline (pre-treatment) 3D-ADC (volumetric) of metastatic lesions was calculated employing prototype software. RECIST 1.1 was used to assess short-term response to treatment. Prediction of response to treatment by baseline 3D-ADC and 2D-ADC (ROI-based) was also compared in all patients. Results: Partial response to treatment (minimum 30% decrease in tumor largest transverse diameter) was seen in 35.3% of patients; 41.2% with systemic chemotherapy, 32.4% with TACE, and 35.3% with 90Y radioembolization (p = 0.82). Median baseline 3D-ADC was significantly lower in responding than in nonresponding lesions. Area under the curve (AUC) of 3D-ADC was 0.90 in 90Y radioembolization patients, 0.88 in TACE patients, and 0.77 in systemic chemotherapy patients (p < 0.01). Optimal prediction was observed with the 10th percentile of ADC (1006 × 10−6 mm2/s), yielding sensitivity and specificity of 77.4% and 91.3%, respectively. 3D-ADC outperformed 2D-ADC in predicting response to treatment (AUC; 0.86 vs. 0.71; p < 0.001). Conclusion: Baseline 3D-ADC is a highly specific biomarker in predicting partial short-term response to treatment in hepatic CLMs. Key Points: • Baseline 3D-ADC is a highly specific biomarker in predicting response to different treatments in hepatic CLMs. • The prediction level of baseline ADC is better for90Y radioembolization than for systemic chemotherapy/TACE in hepatic CLMs. • 3D-ADC outperforms 2D-ADC in predicting short-term response to treatment in hepatic CLMs.

Original languageEnglish (US)
JournalEuropean Radiology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Neoplasm Metastasis
Liver
Drug Therapy
Therapeutics
Area Under Curve
Biomarkers
Software
Sensitivity and Specificity
Neoplasms

Keywords

  • Colorectal neoplasms
  • Diffusion magnetic resonance imaging
  • Liver neoplasms
  • RECIST

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases. / Fouladi, Daniel Fadaei; Zarghampour, Manijeh; Pandey, Pallavi; Pandey, Ankur; Varzaneh, Farnaz Najmi; Ghasabeh, Mounes Aliyari; Khoshpouri, Pegah; Kamel, Ihab R.

In: European Radiology, 01.01.2019.

Research output: Contribution to journalArticle

Fouladi, Daniel Fadaei ; Zarghampour, Manijeh ; Pandey, Pallavi ; Pandey, Ankur ; Varzaneh, Farnaz Najmi ; Ghasabeh, Mounes Aliyari ; Khoshpouri, Pegah ; Kamel, Ihab R. / Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases. In: European Radiology. 2019.
@article{c693051962ba4834aff7d6ecf53a1b93,
title = "Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases",
abstract = "Objectives: To examine the value of baseline 3D-ADC and to predict short-term response to treatment in patients with hepatic colorectal metastases (CLMs). Methods: Liver MR images of 546 patients with CLMs (2008–2015) were reviewed retrospectively and 68 patients fulfilled inclusion criteria. Patients had received systemic chemotherapy (n = 17), hepatic trans-arterial chemoembolization or TACE (n = 34), and 90Y radioembolization (n = 17). Baseline (pre-treatment) 3D-ADC (volumetric) of metastatic lesions was calculated employing prototype software. RECIST 1.1 was used to assess short-term response to treatment. Prediction of response to treatment by baseline 3D-ADC and 2D-ADC (ROI-based) was also compared in all patients. Results: Partial response to treatment (minimum 30{\%} decrease in tumor largest transverse diameter) was seen in 35.3{\%} of patients; 41.2{\%} with systemic chemotherapy, 32.4{\%} with TACE, and 35.3{\%} with 90Y radioembolization (p = 0.82). Median baseline 3D-ADC was significantly lower in responding than in nonresponding lesions. Area under the curve (AUC) of 3D-ADC was 0.90 in 90Y radioembolization patients, 0.88 in TACE patients, and 0.77 in systemic chemotherapy patients (p < 0.01). Optimal prediction was observed with the 10th percentile of ADC (1006 × 10−6 mm2/s), yielding sensitivity and specificity of 77.4{\%} and 91.3{\%}, respectively. 3D-ADC outperformed 2D-ADC in predicting response to treatment (AUC; 0.86 vs. 0.71; p < 0.001). Conclusion: Baseline 3D-ADC is a highly specific biomarker in predicting partial short-term response to treatment in hepatic CLMs. Key Points: • Baseline 3D-ADC is a highly specific biomarker in predicting response to different treatments in hepatic CLMs. • The prediction level of baseline ADC is better for90Y radioembolization than for systemic chemotherapy/TACE in hepatic CLMs. • 3D-ADC outperforms 2D-ADC in predicting short-term response to treatment in hepatic CLMs.",
keywords = "Colorectal neoplasms, Diffusion magnetic resonance imaging, Liver neoplasms, RECIST",
author = "Fouladi, {Daniel Fadaei} and Manijeh Zarghampour and Pallavi Pandey and Ankur Pandey and Varzaneh, {Farnaz Najmi} and Ghasabeh, {Mounes Aliyari} and Pegah Khoshpouri and Kamel, {Ihab R}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00330-019-06289-3",
language = "English (US)",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases

AU - Fouladi, Daniel Fadaei

AU - Zarghampour, Manijeh

AU - Pandey, Pallavi

AU - Pandey, Ankur

AU - Varzaneh, Farnaz Najmi

AU - Ghasabeh, Mounes Aliyari

AU - Khoshpouri, Pegah

AU - Kamel, Ihab R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: To examine the value of baseline 3D-ADC and to predict short-term response to treatment in patients with hepatic colorectal metastases (CLMs). Methods: Liver MR images of 546 patients with CLMs (2008–2015) were reviewed retrospectively and 68 patients fulfilled inclusion criteria. Patients had received systemic chemotherapy (n = 17), hepatic trans-arterial chemoembolization or TACE (n = 34), and 90Y radioembolization (n = 17). Baseline (pre-treatment) 3D-ADC (volumetric) of metastatic lesions was calculated employing prototype software. RECIST 1.1 was used to assess short-term response to treatment. Prediction of response to treatment by baseline 3D-ADC and 2D-ADC (ROI-based) was also compared in all patients. Results: Partial response to treatment (minimum 30% decrease in tumor largest transverse diameter) was seen in 35.3% of patients; 41.2% with systemic chemotherapy, 32.4% with TACE, and 35.3% with 90Y radioembolization (p = 0.82). Median baseline 3D-ADC was significantly lower in responding than in nonresponding lesions. Area under the curve (AUC) of 3D-ADC was 0.90 in 90Y radioembolization patients, 0.88 in TACE patients, and 0.77 in systemic chemotherapy patients (p < 0.01). Optimal prediction was observed with the 10th percentile of ADC (1006 × 10−6 mm2/s), yielding sensitivity and specificity of 77.4% and 91.3%, respectively. 3D-ADC outperformed 2D-ADC in predicting response to treatment (AUC; 0.86 vs. 0.71; p < 0.001). Conclusion: Baseline 3D-ADC is a highly specific biomarker in predicting partial short-term response to treatment in hepatic CLMs. Key Points: • Baseline 3D-ADC is a highly specific biomarker in predicting response to different treatments in hepatic CLMs. • The prediction level of baseline ADC is better for90Y radioembolization than for systemic chemotherapy/TACE in hepatic CLMs. • 3D-ADC outperforms 2D-ADC in predicting short-term response to treatment in hepatic CLMs.

AB - Objectives: To examine the value of baseline 3D-ADC and to predict short-term response to treatment in patients with hepatic colorectal metastases (CLMs). Methods: Liver MR images of 546 patients with CLMs (2008–2015) were reviewed retrospectively and 68 patients fulfilled inclusion criteria. Patients had received systemic chemotherapy (n = 17), hepatic trans-arterial chemoembolization or TACE (n = 34), and 90Y radioembolization (n = 17). Baseline (pre-treatment) 3D-ADC (volumetric) of metastatic lesions was calculated employing prototype software. RECIST 1.1 was used to assess short-term response to treatment. Prediction of response to treatment by baseline 3D-ADC and 2D-ADC (ROI-based) was also compared in all patients. Results: Partial response to treatment (minimum 30% decrease in tumor largest transverse diameter) was seen in 35.3% of patients; 41.2% with systemic chemotherapy, 32.4% with TACE, and 35.3% with 90Y radioembolization (p = 0.82). Median baseline 3D-ADC was significantly lower in responding than in nonresponding lesions. Area under the curve (AUC) of 3D-ADC was 0.90 in 90Y radioembolization patients, 0.88 in TACE patients, and 0.77 in systemic chemotherapy patients (p < 0.01). Optimal prediction was observed with the 10th percentile of ADC (1006 × 10−6 mm2/s), yielding sensitivity and specificity of 77.4% and 91.3%, respectively. 3D-ADC outperformed 2D-ADC in predicting response to treatment (AUC; 0.86 vs. 0.71; p < 0.001). Conclusion: Baseline 3D-ADC is a highly specific biomarker in predicting partial short-term response to treatment in hepatic CLMs. Key Points: • Baseline 3D-ADC is a highly specific biomarker in predicting response to different treatments in hepatic CLMs. • The prediction level of baseline ADC is better for90Y radioembolization than for systemic chemotherapy/TACE in hepatic CLMs. • 3D-ADC outperforms 2D-ADC in predicting short-term response to treatment in hepatic CLMs.

KW - Colorectal neoplasms

KW - Diffusion magnetic resonance imaging

KW - Liver neoplasms

KW - RECIST

UR - http://www.scopus.com/inward/record.url?scp=85067895302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067895302&partnerID=8YFLogxK

U2 - 10.1007/s00330-019-06289-3

DO - 10.1007/s00330-019-06289-3

M3 - Article

C2 - 31209620

AN - SCOPUS:85067895302

JO - European Radiology

JF - European Radiology

SN - 0938-7994

ER -